CAR-T cell therapy for relapsed blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that is CD19, CD20, CD22, or BCMA positive, like certain leukemias, lymphomas, or multiple myeloma.
- Your cancer must have relapsed (come back) or not responded to at least one or more prior treatments.
- You must be between 14 and 75 years old.
- You must be in fairly good health, able to do daily activities, with adequate organ function.
- You must not have certain severe heart, lung, or other conditions, or active infections like HIV or hepatitis.
- You must avoid specific medications before the cell collection and during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.